ArticleDiscover oncology2026
Analysis of prognostic factors related to pulmonary metastasectomy for hepatocellular carcinoma following liver resection.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary metastasectomy improves survival in selected patients with malignancies such as colorectal carcinoma and osteosarcoma. As the most common site of extrahepatic recurrence in hepatocellular carcinoma (HCC), pulmonary metastases are increasingly considered for surgical resection. However, the criteria for patient selection and the indications for surgery remain poorly defined. This study aimed to identify prognostic factors to guide patient selection for pulmonary metastasectomy in HCC.
methodsWe conducted a retrospective analysis of 46 HCC patients who underwent pulmonary metastasectomy at our institution between January 2015 and January 2022. Progression-free survival (PFS) and overall survival (OS) were analyzed to identify prognostic factors. The predictive performance of independent factors was evaluated using receiver operating characteristic (ROC) curves. Immunohistochemical staining for molecular markers was performed on primary HCC tissues from 33 patients to assess their prognostic value.
resultsAmong the 46 patients, 29 (63.0%) experienced recurrence after metastasectomy. The median PFS was 9.2 months, with a median follow-up of 28.5 months. Univariate analysis identified a disease-free interval (DFI) > 12 months (p < 0.001) and histological grade 2 (p = 0.042) as significant predictors of improved PFS, while a maximum pulmonary metastasis diameter ≤ 1.3 cm (p = 0.003) was associated with improved OS. Multivariate analysis confirmed DFI > 12 months as an independent prognostic factor for PFS (p = 0.006), and both DFI > 12 months (p = 0.047) and pulmonary metastasis diameter ≤ 1.3 cm (p = 0.003) for OS. ROC analysis demonstrated that the combination of DFI (AUC = 0.752) and metastasis diameter (AUC = 0.708) provided superior predictive value for OS (AUC = 0.771; p = 0.007). Furthermore, high CD8+ (p = 0.037), low CD68+ (p = 0.045), and FOXP3+ (p = 0.036) expression in primary HCC were significantly associated with better PFS and remained independent prognostic factors in the multivariate model.
conclusionsA DFI > 12 months and a maximum pulmonary metastasis diameter ≤ 1.3 cm are independent prognostic factors in HCC patients undergoing pulmonary metastasectomy, and their combination provides excellent predictive value. An immune-favorable microenvironment in the primary tumor is also associated with improved outcomes. These findings support aggressive surgical management of pulmonary metastases in carefully selected HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.